Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Makiko Ban-Hoefen, MD, Jonathan W. Friedberg, MD, Jennifer L. Kelly, PhD, MPH, Steven H. Bernstein, MD, Jane L. Liesveld, MD, Faith Young, MD, Richard I Fisher, MD, Louis Constine, MD, Michael Becker, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 2393.

https://doi.org/10.1182/blood.V116.21.2393.2393

Published: 2010

Journal Articles

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Jennifer L Kelly, PhDMPH, Faith Young, MD, Jane Liesveld, MD, James O. Armitage, M.D., Nicole Proia, MPH, Kim Cruttenden, N.P., John P. Leonard, MD

Blood (2009) 114 (22): 924.

https://doi.org/10.1182/blood.V114.22.924.924

Published: 2009

Journal Articles

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Manzurul A. Sikder, MD, Sughosh Dhakal, Jennifer Kelly, MPH, Steven H. Bernstein, MD, Faith Young, MD, Richard I. Fisher, MD, Jonathan Friedberg, MD, Louis Constine, MD

Blood (2007) 110 (11): 3433.

https://doi.org/10.1182/blood.V110.11.3433.3433

Published: 2007

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

Journal Articles

Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.

Craig A. Mullen, MD, PhD, Andrew Campbell, MS, Faith Young, MD, Craig T. Jordan, PhD

Blood (2006) 108 (11): 3247.

https://doi.org/10.1182/blood.V108.11.3247.3247

Published: 2006

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

Update search

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only